Wakefield Asset Management Lllp Supernus Pharmaceuticals, Inc. Transaction History

Wakefield Asset Management Lllp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 01, 2023	SELL	$27.57 - $32.91 $25,309 - $30,211	-918 Reduced 4.21%	20,874 $575,000
Q2 2023 Jul 31, 2023	BUY	$29.91 - $38.73 $651,798 - $844,004	21,792 New	21,792 $655,000
Q1 2022 May 02, 2022	SELL	$28.51 - $32.9 $792,720 - $914,784	-27,805 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$26.37 - $34.22 $733,217 - $951,487	27,805 New	27,805 $811,000
Q3 2020 Oct 23, 2020	SELL	$20.2 - $25.05 $440,986 - $546,866	-21,831 Closed	0 $0
Q2 2020 Jul 28, 2020	BUY	$17.09 - $24.89 $373,091 - $543,373	21,831 New	21,831 $518,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Wakefield Asset Management Lllp, based on Form 13F filings with the SEC.

Stay updated on Wakefield Asset Management Lllp with notifications on news.